Skip to content

Adapting LFI for Melioidosis

Adapting a Rapid Lateral Flow Burkholderia Pseudomallei Immunoassay in Sarawak, Malaysia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03528265
Enrollment
100
Registered
2018-05-17
Start date
2018-06-21
Completion date
2019-01-08
Last updated
2019-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melioidosis

Keywords

lateral flow immunoassay, validation

Brief summary

Towards the goal of reducing melioidosis, this study will help clinicians in Sarawak to diagnose and understand the causes and risk factors for melioidosis. The data will help the clinicians to provide faster test results and better clinical care. The investigator's laboratory efforts will supplement available diagnostics by adding a new, easier-to-use test involving lateral flow immunoassay to rapidly detect Burkholderia pseudomallei, a bacterium causing melioidosis. The study aims to study up to 400 patients with melioidosis-like symptoms who are admitted to Kapit Hospital, Sarawak, Malaysia. No participants will be enrolled from other sites. The study will also examine the demographic, behavioral and occupational risk factors associated with hospital admissions to understand any existing associations between these variables and melioidosis prevalence.

Interventions

DEVICELateral flow immunoassay

Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis

Sponsors

Duke University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
No

Inclusion criteria

* Admitted to Kapit Hospital * Fever more than 3 days and one or more of the following: * Enlarged cervical, inguinal or axillary lymph nodes (greater than 3 cm in diameter), painless adenopathy or lymphadenitis or lymph node abscesses * One or both sides glands involvement such as tender swelling over medial aspect of the lower eyelid of the lacrimal glands; submandibular glands, parotic glands * Bedside scan with splenic or liver hypoechoic lesion (less than 2cm in diameter) * Pneumonia not responding to 48 hours of first line antibiotics * One or more joint pain with swelling * Purplish vesicle or bullae mainly over the lower limbs, may resulting in ulcer after rupture * Deep seated abscess or brain abscess or genitourinary abscess or osteomyelitis * Severe sepsis patient with or without shock and/or with multiorgan involvement

Exclusion criteria

* Have a clear alternative diagnosis other than melioidosis by a trained health care professional at the Kapit Hospital * Have already been treated for melioidosis (e.g. received antibiotics before the start of the study) * Are younger than 6 months of age

Design outcomes

Primary

MeasureTime frameDescription
Proportion of true positiveup to 5 weeksProportion of true positive of Bukholderia pseudomallei using rapid diagnostic tests compared to the results of qPCR, bacterial culture and Gram stain
Proportion of true negativeup to 5 weeksProportion of true negative of Bukholderia pseudomallei using rapid diagnostic tests compared to the results of qPCR, bacterial culture and Gram stain

Secondary

MeasureTime frameDescription
Statistical association between risk factors and test resultsup to 3 monthsconduct a survey to determine a statistical association between clinical risk factors and the test results combined

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026